HIMS Stock Forecast & Price Target

Hims & Hers Health is experiencing significant growth, with a notable 55% year-over-year increase in members utilizing personalized products, contributing to nearly 65% of total membership as of 3Q:25. The company forecasts a substantial rise in international revenue, projecting it to reach nearly $1 billion by FY30, driven by expanded treatment offerings, entry into new markets, and enhancements to user experience, building on an estimated $50 million in FY25 revenue. Additionally, Hims & Hers anticipates core U.S. revenue to grow approximately 21% annually, fueled by subscriber growth and increased revenue per subscriber through personalization and cross-selling of premium treatments.

Hims & Hers Health has experienced a significant downturn in stock value, with a more than 20% decline since late July, raising concerns regarding slowing core growth despite an overall doubling of shares year-to-date. Key challenges include a slower adoption of personalized treatments, potential regulatory changes affecting the telehealth business model, and the company’s struggle to maintain revenue growth while achieving operational efficiency amidst heightened competition in the digital health sector. Furthermore, the company's reliance on consumer financial health poses additional risks, as a downturn in the macroeconomic environment could reduce disposable income and negatively impact demand for healthcare subscriptions.